Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
A-Z
> Exhibition > From Bench to Breakthrough: Translating Autoimmune Research into Life-Changing Therapies
From harnessing NK cell engagers for cancer and autoimmune treatments to optimizing recombinant protein production for biologic drug development, innovation is rapidly transforming the therapeutic landscape. However, key challenges—such as improving NK cell activation, antibody specificity, and scalable protein expression—continue to slow progress.
What You’ll Learn:
- Redefining NK Cell Engagers: Discover how AvantGen’s Germliner™ Library Collection has led to fully human, highly specific CD16a antibodies that enhance NK cell-mediated cytotoxicity in novel therapeutic formats.
- Optimizing Protein Engineering for Drug Development: Learn how ACROBiosystems has built next-generation platforms to produce high-quality recombinant proteins essential for developing targeted therapies in autoimmune disease and beyond.
- Real-World Case Studies: Gain actionable insights from real-world applications addressing key challenges in antibody discovery, NK cell activation, and scalable protein production.
Whether you’re working in immuno-oncology, autoimmune research, or biologics manufacturing, this webinar offers a deep dive into groundbreaking strategies that accelerate therapeutic breakthroughs. Don’t miss this opportunity to engage with industry leaders and stay ahead in the rapidly evolving biopharma landscape!
Jordon Wang, PhD.
COO and Senior VP, Technology Development AvantGen
Dr. Jordon Wang is the Chief Operating Officer and Senior Vice President of Technology Development at AvantGen. The team is dedicated to accelerating antibody-based therapeutics for their scientific partners by using innovative platforms. Before joining AvantGen, Jordon served as VP of Technology Development and VP of Antibody Discovery at LakePharma, now part of Curia. He earned a B.S. in Biological Sciences and a Ph.D. in Cancer Biology at Stanford University
Talk Title: Development of an NK Cell Engager Utilizing Antibodies Targeting a Single Amino Acid Variation
Talk Abstract: Natural killer (NK) cells play a vital role in the human innate immune system, and NK cell engagers are being explored as a promising approach for cancer and autoimmune disease immunotherapy. Using AvantGen's Germliner™ Library Collection, we've isolated and developed a panel of highly specific, fully human CD16a antibodies that exhibit potent activities in killing target cells in various NK cell engager formats.
Peter Hsueh, PhD.
Marketing Product Manager ACROBiosystems
Peter Hsueh, Ph.D., is a dynamic Marketing Product Manager at ACROBiosystems,a leader in developing and manufacturing recombinant proteins and critical reagents/assays to support therapeutic development. Leveraging his extensive technical expertise in molecular biology and biomarker research, Peter aims to shape impactful marketing strategies that resonate within the life science community. Formerly a Field Application Scientist, Peter brings a wealth of experience in customer technical support, allowing him to understand and address the unique needs of customers. Driven by a passion for both science and marketing, Peter is committed to steering ACROBiosystems towards new horizons through targeted marketing initiatives.
Talk Title: Exploring Popular Target Proteins in Autoimmune Diseases: Design, Development, and Applications
Talk Abstract: Recombinant protein production is pivotal for developing targeted therapies in autoimmune diseases. This talk explores the evolution of autoimmune therapeutics and key historical milestones that have driven current innovations. Leveraging over a decade of experience, ACROBiosystems has engineered robust platforms to generate high-quality protein targets essential for research and drug development. Three case studies illustrate challenges in protein expression and present strategies to overcome them. This presentation underscores the impact of optimized protein production on advancing autoimmune therapy and outlines promising directions for future research.
This web search service is supported by Google Inc.
